- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC
S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
S. Daniel Haldar, MD, an assistant professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and an adjunct assistant professor in the Department of Oncology at Johns Hopkins University School of Medicine, discussed outcomes for the personalized neoantigen vaccine NeoAg-VAX with or without pembrolizumab (Keytruda) in patients with microsatellite stable metastatic colorectal cancer.
Related Content:
